GSK, RSV and Arexvy
GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for RSV, a common respiratory virus that can lead to serious negative clinical outcomes,
GSK's respiratory syncytial virus vaccine approved in M'sia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory virus that can lead to serious negative clinical outcomes,
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
NHL fans displeased with Wayne Gretzky's new commercial for AREXVY vaccine. (Image Source: Imagn). NHL fans have expressed their dissatisfaction on social media regarding Wayne Gretzky's latest ...
These vaccines-Arexvy by GSK and Abrysvo by Pfizer—are the first for RSV. The new vaccines come with common vaccine side effects including swelling or pain at the injection site, fever, and headache ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback